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Abstract. Due to the highly glycolytic metabolism of solid tumours, there is an increased acid production, however, cells
are able to maintain physiological pH through plasma membrane efflux of the accumulating protons. Acid efflux through
MCTs (monocarboxylate transporters) constitutes one of the most important mechanisms involved in tumour intracellular pH
maintenance. Still, the molecular mechanisms underlying the regulation of these proteins are not fully understood. We aimed
to evaluate the association between CD147 (MCT1 and MCT4 chaperone) and MCT expression in cervical cancer lesions and
the clinico-pathological significance of CD147 expression, alone and in combination with MCTs. The series included 83 biopsy
samples of precursor lesions and surgical specimens of 126 invasive carcinomas. Analysis of CD147 expression was performed
by immunohistochemistry. CD147 expression was higher in squamous and adenocarcinoma tissues than in the non-neoplastic
counterparts and, importantly, both MCT1 and MCT4 were more frequently expressed in CD147 positive cases. Additionally,
co-expression of CD147 with MCT1 was associated with lymph-node and/or distant metastases in adenocarcinomas. Our results
show a close association between CD147 and MCT1 and MCT4 expressions in human cervical cancer and provided evidence for
a prognostic value of CD147 and MCT1 co-expression.
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1. Introduction
In order to maintain high growth rates in hypoxic
environment, cancer cells switch to anaerobic glycoly-
sis to obtain energy. Actually, this metabolic change is
maintained even in the presence of oxygen,as described
by Warburg [1]. One consequence of cytosolic glucose
metabolism is the increase in intracellular lactic acid
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concentration, which has to be tightly regulated to al-
low tumour cell survival and proliferation. Acid efflux
through Monocarboxylate Transporters (MCTs) con-
stitutes one of the most important mechanisms involved
in the maintenance of tumour intracellular pH [2]. In-
deed, MCT upregulation has been recently reported in
some tumours, including brain [3–5], colorectal [6,7],
lung [8] and, more recently, we described upregulation
of MCT1 and 4 in cervical cancer [9].
MCT expression appears to be influenced by al-
tered physiologic conditions, however, the underlying
molecular events involved in MCT regulation are poor-
ly understood. Recently, it was demonstrated that prop-
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er expression and activity of MCT1 and MCT4 re-
quires an ancillary protein known as CD147 or EMM-
PRIN [10–12]. On the other hand, silencing studies
showed that maturation and cell surface expression of
CD147 depends on MCT1 and MCT4 expressions [13,
14]. CD147 has already been described as a key el-
ement in tumour growth and metastasis by stimulat-
ing the synthesis of several matrix metalloproteinas-
es, leading to enhanced tumour cell invasion [15,16],
and also by stimulating angiogenesis [17]. This pro-
tein is described to be up-regulated in several human
cancers [16,18,19], including cervical squamous cell
carcinoma [20], where it was found to correlate with
pelvic lymph-node metastasis and resistance to radio-
therapy [21].
Given that CD147 is described as an MCT regulator,
we aimed to assess the association between CD147 and
MCT1, MCT2 and MCT4 expressions, in a large and
complete series of cervical lesions. Also, and since
CD147 is poorly explored in cervical carcinoma, we
intended to unveil the prognostic value of CD147 ex-
pression, alone and in combination with MCTs.
2. Materials and methods
2.1. Case selection
The material studied comprised 83 formalin-fixed
paraffin embedded samples selected from the files of
Pathology Division of Adolfo Lutz Institute, Sa˜o Paulo,
Brazil, which included biopsies of 28 chronic cervici-
tis (herein designated as “negative” for HPV-induced
lesion), 26 Cervical Intraepithelial Neoplasia grade I
(CIN 1, herein designated as low-grade squamous in-
traepithelial lesion – LSIL) and 29 Cervical Intraep-
ithelial Neoplasia grades II and III (CIN2/3, herein des-
ignated as high-grade squamous intraepithelial lesions
- HSIL). We also analyzed a series of formalin-fixed,
paraffin-embedded tissue samples from 126 patients
with squamous cells carcinoma (SCC, n = 49), ade-
nocarcinoma (AC, n = 50) and adenosquamous car-
cinoma (ASC, n = 27) of the uterine cervix, exam-
ined and treated at two Institutions: Arau´jo Jorge Hos-
pital and the Pathology Department of the School of
Medicine of the Federal University of Goia´s, Goiania,
in Goia´s State, Brazil. All histopathological diagnoses
were revised and categorized according to the WHO
classification [22]. Clinico-pathological data of the pa-
tients included age at diagnosis, HPV status, lymph-
node and/or distant metastasis, recurrence and overall
survival.
2.2. MCT immunohistochemistry
Data on MCT1, MCT2 and MCT4 expressions was
available for all the 209 samples [9]. MCT immuno-
histochemistry was performed according to avidin-
biotin-peroxidase complex principle (R.T.U. VECTAS-
TAIN Elite ABC Kit (Universal), Vector Laboratories,
Burlingame, CA, USA), with the primary antibodies
for MCT1 (AB3538P, Chemicon International, Temec-
ula, CA, USA), MCT2 (sc-14926, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and MCT4 (AB3316P,
Chemicon International, Temecula, CA, USA), diluted
1:200, as previously described [7].
2.3. CD147 immunohistochemistry
CD147 immunohistochemistrywas performed based
on the streptavidin–biotin–peroxidase complex prin-
ciple (Ultravision Detection System Anti-polyvalent,
HRP, Lab Vision Corporation, Fremont, CA), using
a primary antibody raised against CD147 (18-7344,
ZYMED Laboratories Inc., South San Francisco, CA,
diluted 1:750). Briefly, deparaffinized and rehydrat-
ed sections were immersed in EDTA (pH 8.0), heat-
ed up to 98◦C in a water bath for 15 minutes and
washed in PBS. Endogenous peroxidases were inacti-
vated with 3% hydrogen peroxide in methanol for 10
minutes, followed by washing in PBS. Tissue sections
were incubated with blocking solution for 10 minutes
and incubated at room temperature with the primary
antibody for 2 hours. Sections were then sequentially
washed in PBS and incubated with biotinylated goat
anti-polyvalent antibody for 10 minutes, streptavidin
peroxidase for 10 minutes, and developed with 3,3’-
diamino-benzidine (DAB+ Substrate System, Dako,
Carpinteria, CA) for 10 minutes. Negative controls
were performed by using the adequate serum control
(N1698, Dako, Carpinteria, CA) and cervical squa-
mous carcinoma was used as positive control. Tissue
sections were counterstained with haematoxylin and
permanently mounted.
2.4. Immunohistochemical evaluation
Sections were evaluated for immunoreaction, which
included cytoplasmic and/or membrane positive stain-
ing. Immunoreaction extent was scored semi-
quantitatively as follows: 0: 0% of immunoreactive
cells; 1: < 5% of immunoreactive cells; 2: 5–50% of
immunoreactive cells; and 3: > 50% of immunoreac-
tive cells. Also, intensity of staining was scored semi-
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qualitatively as 0: negative; 1: weak; 2: intermediate;
and 3: strong. Immunoreaction final score was defined
as the sum of both parameters (extent and intensity),
and grouped as negative (score 0 and 2) and positive
(3–6), as previously described [7]. Finally, since plas-
ma membrane location of CD147 is essential for MCT1
and MCT4 membrane localization and activity [10–12],
we also grouped the plasma membrane positive cases,
including all the positive cases, with or without cyto-
plasmic expression. Immunohistochemical evaluation
was performed blindly by two independent observers
and discordant results were discussed in a double-head
microscope and a final score was agreed.
2.5. Statistical analysis
Data were stored and analyzed using the SPSS sta-
tistical software (version 14.0, SPSS Inc., Chicago, IL,
USA). The comparison of CD147 expression between
tumor and normal cells as well as the relationship be-
tween CD147 expression and the clinico-pathological
parameters were examined for statistical significance
using Pearson’s chi-square (χ2) test and Fisher’s exact
test (when n < 5), being threshold for significance p
values < 0.05. The same analysis was performed in
order to compare CD147 expression with MCTs. Sur-
vival curves were plotted using the method of Kaplan
and Meier and data compared using the log-rank test,
using a cut-off of 24 months. Due to lack of infor-
mation, 18 cases of SCC and 1 case of ASC were not
evaluated for clinico-pathological significance.
3. Results
We analyzed the expression of CD147 in a series of
cervical samples which included 83 biopsies of cervix
intraepithelial lesions and 126 surgical specimens of
invasive cervical carcinomas. CD147 expression was
mainly found in the plasma membrane (Fig. 1), with
cases presenting both membrane and cytoplasmic stain-
ing and some only cytoplasmic expression. Figure 2
compares the frequency of CD147 expression in all the
squamous epithelial lesions studied, as well as non-
neoplastic and neoplastic glandular tissues. CD147 ex-
pression was significantly different in the various squa-
mous epithelial lesions (p < 0.001, Fig. 2), showing a
more frequent expression in squamous neoplasias than
in their non-neoplastic counterparts. Concerning the
glandular epithelium, since our series does not include




Fig. 1. Immunohistochemical expression of CD147 in cervical le-
sions. Representative cases of CD147 expression in: high-grade
squamous intraepithelial lesion (A); squamous cell carcinoma (B);
adenocarcinoma (C). All pictures are at 400X magnification.
to compare neoplastic lesions (AC) with non-neplastic
glandular tissue from the biopsy material. Here, an ev-
ident gain in CD147 expression was observed in ade-
nocarcinoma tumour cells (Fig. 1C), when compared
to normal glandular tissue (p < 0.001, Fig. 2).
HPV status of the biopsy material was known and
samples included 50/88 high risk HPV positive cases
(6/28 cervicitis, 16/26 LSIL and 28/29 HSIL); howev-
er, no association was found between HPV infection
and CD147 expression (data not shown). The clinico-
pathological significance of CD147 expression, as well
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Fig. 2. Frequency of CD147 staining in all squamous lesions studied, including non-neoplastic and neoplastic glandular tissues. “Immunoreaction”
refers to both cytoplasmic and membrane positive staining; “membrane” refers to plasma membrane positive cases, with or without cytoplasmic
expression; anegative for HPV-induced cervical lesions; bnon-neoplastic glandular epithelium; continuous line: statistical significance for
immunoreaction results; interrupted line: statistical significance for membrane staining results; *p < 0.001; **p = 0.001. LSIL – low-grade
squamous intraepithelial lesion; HSIL – high-grade squamous intraepithelial lesion; SCC – squamous cell carcinoma; AC – adenocarcinoma.
as co-expression of CD147 and both MCT1 and MCT4
was assessed for 99 carcinomas (Table 1). Consid-
ering all primary tumours, no association was found
with the clinico-pathological data; however, since the
3 histological types behave differently and probably
present different metabolic activity, associations were
assessed by histological type. Regarding individual
expression of CD147, no significant associations were
observed, but co-expression of CD147 with MCT1 was
significantly associated with lymph-node and/or distant
metastases in adenocarcinomas (p = 0.033). No statis-
tically significant associations were found with survival
data (data not shown).
Consistent with the assumption that CD147 func-
tions as a regulator of MCT1 and MCT4 expressions,
we observed that both MCT1 and MCT4 correlated
with CD147 immunoreaction (p = 0.001 for MCT1
immunoreaction and MCT4 plasma membrane expres-
sion; p = 0.002 for MCT1 plasma membrane expres-
sion and MCT4 immunoreaction, Table 2), while on-
ly MCT4 immunoreaction was associated with plas-
ma membrane expression of CD147 (p = 0.014, Ta-
ble 2). As anticipated, no association was found be-
tween CD147 and MCT2 expressions.
4. Discussion
MCTs were recently described as crucial proteins in
cancer cell pH homeostasis [2]. Although regulation
of MCT expression is still far from being well under-
stood, one of the best characterized MCT regulation
mechanisms is through the co-expression with CD147
at the plasma membrane [10–13].
The important contribution of CD147 in promoting
tumour growth, invasion and metastasis has been wide-
ly explored in past years [16,19], however, in what con-
cerns cervical cancer, this issue is far from being clar-
ified. Here, we describe the expression of CD147 in
a complete series of cervical carcinoma but also look
at an important feature of this protein, little explored
in cancer: the association with MCTs. In the present
study, we observed an increase in CD147 expression in
both squamous and glandular tumours, when compared
to non-neoplastic corresponding tissues. Nonetheless,
in opposition to previous results from Sier and collab-
orators [20], who described no staining in normal ep-
ithelial cells, we observed a considerable expression of
CD147 in the non-neoplastic epithelium. However, the
non-neoplastic epithelium herein described was in fact
biopsy material from cervicitis, which may explain the
presence of CD147, knowing that this protein has a role
in inflammation [23]. The frequency of CD147 expres-
sion in our tumour series was around 70%, which is in
accordance with previous results in cervical squamous
cell carcinomas [21]. In opposition to what we previ-
ously observed for MCT2 and MCT4 [9], CD147, like
MCT1, was not differently expressed among the three
histological types studied and no association was ob-
served with the clinico-pathological data, namely with
lymph-nodemetastases, contrasting with what has been
recently described [21].
Taking into consideration the close association be-
tween CD147 and MCTs [10–14], we sought for cor-
relations between these proteins in a series of cervical
lesions. We observed that both MCT1 and MCT4 over-
expressions correlated with CD147, while only MCT4
was associated with CD147 plasma membrane stain-
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Table 1
Correlation of CD147 and combined CD147 and MCT expressions with the clinico-pathological data of carcinoma cases
Expression CD147 CD147 CD147+MCT1 CD147+MCT4
immunoreaction membrane
Clinical data n Positive (%) p Positive (%) p Positive (%) p Positive (%) p
All carcinomas
Agea 0.204 0.941 0.598 0.200
> 49 48 64.6 45.8 16.7 19.1
 49 58 75.9 46.6 20.7 10.3
Histological type 0.734 0.755 0.819 0.683
SCC 49 71.4 38.8 16.3 10.2
AC 50 70.0 46.0 20.0 16.0
ASC 27 63.0 44.4 14.8 14.8
Lymph node/metastasesb 0.539 0.254 0.149 0.376
Absent 79 69.6 43.0 15.2 12.8
Present 25 76.0 56.0 28.0 20.0
Recurrence 1.000 0.729 0.667 0.495
Negative 95 70.5 45.3 17.9 13.8
Positive 9 77.8 55.6 22.2 22.2
SCC
Agea 1.000 0.576 0.664 0.607
> 49 14 78.6 42.9 14.3 7.1
 49 17 82.4 52.9 23.5 17.6
Lymph node/metastasesb 0.553 0.172 1.000 0.112
Absent 26 76.9 42.3 19.2 7.7
Present 5 100.0 80.0 20.0 40.0
Recurrence
Negative 31 80.6 48.4 19.4 12.9
Positive 0
AC
Agea 0.305 0.674 0.942 0.130
> 49 24 62.5 50.0 20.8 26.1
 49 25 76.0 44.0 20.0 8.0
Lymph node/metastasesb 0.405 0.446 0.033 0.613
Absent 39 66.7 43.6 12.8 15.8
Present 8 87.5 62.5 50.0 25.0
Recurrence 0.657 0.690 1.000 0.587
Negative 40 67.5 45.0 20.0 15.4
Positive 7 85.7 57.1 14.3 28.6
ASC
Agea 0.339 1.000 1.000 0.538
> 49 10 50.0 40.0 10.0 20.0
 49 16 68.8 43.8 18.8 6.3
Lymph node/metastasisb 0.756 0.951 1.000 1.000
Absent 14 64.3 42.9 14.3 14.3
Present 12 58.3 41.7 16.7 8.3
Recurrence 1.000 1.000 0.289 1.000
Negative 24 62.5 41.7 12.5 12.5
Positive 2 50.0 50.0 50.0 0.0
aThe age cut off was considered as the mean age of the patients at time of diagnosis;bLymph node/metastasis includes both lymph-node and
distant metastases. “CD147+MCT isoform” refers to co-expression of CD147 and MCT in the plasma membrane. SCC – squamous cell
carcinoma; AC – adenocarcinoma; ASC – adenosquamous carcinoma.
“Immunoreaction” refers to both cytoplasmic and membrane positive staining; “membrane” refers to plasma membrane positive cases, with or
without cytoplasmic expression.
ing. Although it was expectable to found correlations
between membrane expressions, since part of the reg-
ulation involves membrane co-localization of the pro-
teins [10,11], absence of CD147 is also responsible
for lower levels of MCT1 and MCT4 whole protein
expression [12] and for endolysosomal degradation of
MCT4 [13], explaining the association between overall
expressions. As anticipated, since the MCT2 chaper-
one is not CD147 but gp70 [11] and lack of CD147
does not affect MCT2 protein levels [12], we found
no association between CD147 and MCT2 expression.
Knowing that MCTs need to interact with CD147 to be
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Table 2
Correlation between MCT and CD147 expressions in all cervical lesions
MCT isoform CD147 CD147
Immunoreaction Plasma membrane
n Positive (%) p Positive (%) p
MCT1 immunoreaction 0.001 0.110
Negative 142 43.7 32.4
Positive 109 64.2 42.2
plasma membrane 0.002 0.182
Negative 179 46.4 34.1
Positive 72 68.1 43.1
MCT2 immunoreaction 0.322 0.389
Negative 106 50.0 40.6
Positive 142 56.3 35.2
MCT4 immunoreaction 0.002 0.014
Negative 126 44.4 30.2
Positive 119 63.9 45.4
plasma membrane 0.001 0.146
Negative 210 49.5 35.7
Positive 35 80.0 48.6
“Immunoreaction” refers to both cytoplasmic and membrane positive staining; “membrane”
refers to plasma membrane positive cases, with or without cytoplasmic expression.
functionally active [10,11], we hypothesized that co-
expression of the transporters with the chaperone could
favor the malignant potential of cancer cells. In fact,
we observed that co-expression of CD147 and MCT1
in adenocarcinomas was more frequent in patients with
lymph-node and/or distant metastases, being in accor-
dance with the synergistic activity between MCTs and
CD147, leading to an enhanced metastatic potential
of cancer cells, through acidification of the tumor mi-
croenvironment [13]. Some other possibly relevant as-
sociations did not achieve significance, due to the num-
ber of cases representing each histological type; thus,
larger studies are needed to confirm or decline these
associations.
In sum, we evaluated the clinico-pathological signif-
icance of CD147 in cervical cancer,alone and in combi-
nation with MCTs, and provided evidence for the asso-
ciation between CD147 and both MCT1 and 4 expres-
sions in human samples. We also showed that CD147
and MCT1 co-expression could have a prognostic val-
ue. Nevertheless, further studies are needed to explore
the possible synergistic effect of these molecules in the
metastatic potential of cervical carcinoma cells.
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